{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:55:26Z","timestamp":1791388526293,"version":"4.3.3"},"reference-count":73,"publisher":"Elsevier","isbn-type":[{"value":"9780443431906","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008812","name":"Defence Science and Technology Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRP-2023\\u20131068"],"award-info":[{"award-number":["IIRP-2023\\u20131068"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020622","name":"Translational Health Science and Technology Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.pmbts.2026.01.008","type":"book-chapter","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:39:08Z","timestamp":1769009948000},"page":"209-227","source":"Crossref","is-referenced-by-count":0,"title":["Recombinant live biotherapeutics against chronic metabolic diseases: Challenges and opportunities"],"prefix":"10.1016","author":[{"given":"Prajwal","family":"Swamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakhwinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Sehrawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.pmbts.2026.01.008_bib1","unstructured":"NonCommunicable Diseases Country Profiles 2018. https:\/\/www.who.int\/publications\/i\/item\/ncd-country-profiles-2018, September 24, 2018."},{"issue":"9468","key":"10.1016\/bs.pmbts.2026.01.008_bib2","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/bs.pmbts.2026.01.008_bib3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/dc11-0442","article-title":"Globalization of diabetes: the role of diet, lifestyle, and genes","volume":"34","author":"Hu","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib4","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatology"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders","volume":"542","author":"Hotamisligil","year":"2017","journal-title":"Nature"},{"issue":"17","key":"10.1016\/bs.pmbts.2026.01.008_bib6","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2025.100375","article-title":"Obesity: prevalence, causes, consequences, management, preventive strategies and future research directions","volume":"27","author":"Ahmed","year":"2025","journal-title":"Metab Open"},{"issue":"11","key":"10.1016\/bs.pmbts.2026.01.008_bib8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/bs.pmbts.2026.01.008_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1161521","article-title":"Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments","volume":"14","author":"Ruze","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.008_bib11","first-page":"7","article-title":"IDF diabetes atlas 11th edition 2025: global prevalence and projections for 2050","volume":"41","author":"Duncan","year":"2025","journal-title":"Nephrol\u00a0Dial\u00a0Transplant"},{"issue":"11","key":"10.1016\/bs.pmbts.2026.01.008_bib12","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.2522\/ptj.20080008","article-title":"Diabetes-related microvascular and macrovascular diseases in the physical therapy setting","volume":"88","author":"Cade","year":"2008","journal-title":"Phys Ther"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib13","first-page":"306","article-title":"Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: an update on glucose toxicity","volume":"107","author":"Giri","year":"2018","journal-title":"Biomed\u00a0Pharmacother"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib14","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib15","article-title":"Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: a systematic review","volume":"41","author":"Sanyal","year":"2024","journal-title":"Am Heart J Plus: Cardiology Res Pract"},{"issue":"2","key":"10.1016\/bs.pmbts.2026.01.008_bib16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/HEP.0000000000000735","article-title":"Metabolic dysfunction-associated steatotic liver disease and the heart","volume":"82","author":"Driessen","year":"2025","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/bs.pmbts.2026.01.008_bib17","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"issue":"suppl 1","key":"10.1016\/bs.pmbts.2026.01.008_bib18","first-page":"S10","article-title":"Pathogenesis of MASLD and MASH \u2013 role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib19","unstructured":"World-Heart-Report-2023. https:\/\/world-heart-federation.org\/wp-content\/uploads\/World-Heart-Report-2023.pdf, 2023."},{"key":"10.1016\/bs.pmbts.2026.01.008_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120495","article-title":"Understanding MASLD \u2014 from molecular pathogenesis to cardiovascular risk: A concise review for the clinical cardiologist","volume":"409","author":"Ratti","year":"2025","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.008_bib21","article-title":"Long-term effects of weight-reducing drugs in people with hypertension","volume":"1","author":"Siebenhofer","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/bs.pmbts.2026.01.008_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/bs.pmbts.2026.01.008_bib23","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib24","unstructured":"ADA Standards of Medical Care in Diabetes: Updates! [Internet]. 2025 Available from: https:\/\/www.cdc.gov\/diabetes\/prevention\/find-a-program.html."},{"issue":"6","key":"10.1016\/bs.pmbts.2026.01.008_bib25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/bs.pmbts.2026.01.008_bib26","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/bs.pmbts.2026.01.008_bib27","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/bs.pmbts.2026.01.008_bib28","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/dom.14304","article-title":"Pioglitazone and bariatric surgery are the most effective treatments for non\u2010alcoholic steatohepatitis: A hierarchical network meta\u2010analysis","volume":"23","author":"Panunzi","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"22","key":"10.1016\/bs.pmbts.2026.01.008_bib29","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/bs.pmbts.2026.01.008_bib30","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/bs.pmbts.2026.01.008_bib31","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.3390\/jcm14144834","article-title":"The multidisciplinary approach to GLP-1 RA and SGLT2 inhibitors in cardiometabolic care: a new era for patients with diabetes and heart disease","volume":"14","author":"Luc\u00e0","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib32","article-title":"Live biotherapeutic products, a road map for safety assessment","volume":"7","author":"Rouanet","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib33","article-title":"Entering first-in-human clinical study with a single-strain live biotherapeutic product: input and feedback gained from the EMA and the FDA","volume":"8","author":"Paquet","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.008_bib34","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/s41467-020-15508-1","article-title":"Developing a new class of engineered live bacterial therapeutics to treat human diseases","volume":"11","author":"Charbonneau","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.008_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41522-023-00463-8","article-title":"Recent advances in single-cell engineered live biotherapeutic products research for skin repair and disease treatment","volume":"9","author":"Roslan","year":"2023","journal-title":"NPJ Biofilms Microbiomes"},{"issue":"5","key":"10.1016\/bs.pmbts.2026.01.008_bib36","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cell.2016.08.016","article-title":"DNA phenotyping: snapshot of a criminal","volume":"166","author":"Matheson","year":"2016","journal-title":"Cell"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib37","unstructured":"FDA\u00a0Cber\u00a0Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information; Guidance for Industry [Internet]. Available from: https:\/\/www.fda.gov\/files\/vaccines,%20blood%20%26%20biologics\/published\/Early-Clinical-Trials-With-Live-Biotherapeutic-Products--Chemistry--Manufacturing--and-Control-Information--Guidance-for-Industry.pdf."},{"issue":"11","key":"10.1016\/bs.pmbts.2026.01.008_bib38","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1210\/clinem\/dgae499","article-title":"Exploring the gut microbiota: key insights into its role in obesity, metabolic syndrome, and type 2 diabetes","volume":"109","author":"Sasidharan Pillai","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.571731","article-title":"Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes","volume":"11","author":"Scheithauer","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.008_bib40","doi-asserted-by":"crossref","first-page":"9358","DOI":"10.1038\/s41467-024-53832-y","article-title":"Identification of gut microbiome features associated with host metabolic health in a large population-based cohort","volume":"15","author":"Keshet","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.008_bib41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/bs.pmbts.2026.01.008_bib42","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.008_bib43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s44324-024-00028-z","article-title":"Recent advances in cardiovascular disease research driven by metabolomics technologies in the context of systems biology","volume":"2","author":"Zhang","year":"2024","journal-title":"npj Metab Health Dis"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1085041","article-title":"The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases","volume":"14","author":"Zhen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib45","doi-asserted-by":"crossref","unstructured":"Probiotics, Prebiotics, and Postbiotics in Human Health and Sustainable Food Systems [Working Title].\u00a0IntechOpen; 2024. https:\/\/doi.org\/10.5772\/intechopen.113694.","DOI":"10.5772\/intechopen.113694"},{"issue":"11","key":"10.1016\/bs.pmbts.2026.01.008_bib46","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.3390\/jcm14113673","article-title":"A review of the influence of prebiotics, probiotics, synbiotics, and postbiotics on the human gut microbiome and intestinal integrity","volume":"14","author":"Smolinska","year":"2025","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.008_bib47","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1038\/s41467-019-13336-6","article-title":"Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut","volume":"10","author":"Praveschotinunt","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.lwt.2024.116532","article-title":"Whole genome sequence analysis and in vitro probiotic characteristics of Lactococcus lactis ZFM559","volume":"205","author":"Zhang","year":"2024","journal-title":"LWT"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.008_bib49","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1038\/s41467-024-48128-0","article-title":"Targeted delivery of the probiotic Saccharomyces boulardii to the extracellular matrix enhances gut residence time and recovery in murine colitis","volume":"15","author":"Heavey","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib50","article-title":"Engineered bacteria of MG1363-pMG36e-GLP-1 attenuated obesity-induced by high fat diet in mice","volume":"11","author":"Wang","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"11","key":"10.1016\/bs.pmbts.2026.01.008_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202303958","article-title":"Biochemotaxis\u2010oriented engineering bacteria expressing GLP\u20101 enhance diabetes therapy by regulating the balance of immune","volume":"13","author":"Wang","year":"2024","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.008_bib52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101823","article-title":"Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model","volume":"78","author":"Iannone","year":"2023","journal-title":"Mol Metab"},{"issue":"7","key":"10.1016\/bs.pmbts.2026.01.008_bib54","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41366-025-01774-w","article-title":"The effect of aldafermin expressing-Escherichia coli Nissle 1917 along with dietary change on visceral adipose tissue in MASLD mouse model","volume":"49","author":"Iannone","year":"2025","journal-title":"Int J Obes"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.008_bib55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12934-020-01350-z","article-title":"Engineered butyrate-producing bacteria prevents high fat diet-induced obesity in mice","volume":"19","author":"Bai","year":"2020","journal-title":"Microb Cell Fact"},{"issue":"10","key":"10.1016\/bs.pmbts.2026.01.008_bib56","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3390\/pharmaceutics13101536","article-title":"Oral gene therapy of HFD-obesity via nonpathogenic yeast microcapsules mediated shRNA delivery","volume":"13","author":"Zhang","year":"2021","journal-title":"Pharmaceutics"},{"issue":"16","key":"10.1016\/bs.pmbts.2026.01.008_bib57","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1007\/s00253-019-09958-x","article-title":"Two-week administration of engineered Escherichia coli establishes persistent resistance to diet-induced obesity even without antibiotic pre-treatment","volume":"103","author":"Dosoky","year":"2019","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.008_bib58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3920\/BM2019.0093","article-title":"Recombinant Lactococcus lactis NZ3900 expressing bioactive human FGF21 reduced body weight of Db\/Db mice through the activity of brown adipose tissue","volume":"11","author":"Cao","year":"2020","journal-title":"Benef Microbes"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib59","article-title":"Optogenetic operated probiotics to regulate host metabolism by mimicking enteroendocrine","author":"Zhang","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib60","doi-asserted-by":"crossref","first-page":"118","DOI":"10.37349\/edd.2022.00009","article-title":"Probiotic human alcohol dehydrogenase-4 expressing bacteria protects from diet-induced obesity and metabolic impairment: a new concept of disease prevention","author":"Singh","year":"2022","journal-title":"Exploration Digestive Dis"},{"issue":"11","key":"10.1016\/bs.pmbts.2026.01.008_bib61","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1021\/acssynbio.3c00455","article-title":"Cold exposure and oral delivery of GLP-1R agonists by an engineered probiotic yeast strain have antiobesity effects in mice","volume":"12","author":"Hedin","year":"2023","journal-title":"ACS Synth Biol"},{"issue":"9","key":"10.1016\/bs.pmbts.2026.01.008_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162733","article-title":"Oral delivery of pentameric glucagon-like peptide-1 by recombinant lactobacillus in diabetic rats","volume":"11","author":"Lin","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/bs.pmbts.2026.01.008_bib63","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1021\/acssynbio.2c00314","article-title":"Intestinal engineered probiotics as living therapeutics: chassis selection, colonization enhancement, gene circuit design, and biocontainment","volume":"11","author":"Huang","year":"2022","journal-title":"ACS Synth Biol"},{"issue":"17","key":"10.1016\/bs.pmbts.2026.01.008_bib64","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1016\/j.cell.2022.06.050","article-title":"Intestinal transgene delivery with native E. coli chassis allows persistent physiological changes","volume":"185","author":"Russell","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.008_bib65","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cels.2018.06.008","article-title":"Synthetic biology and engineered live biotherapeutics: toward increasing system complexity","volume":"7","author":"Ozdemir","year":"2018","journal-title":"Cell Syst"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib66","doi-asserted-by":"crossref","first-page":"97","DOI":"10.38212\/2224-6614.3540","article-title":"Regulatory framework and challenges for live biotherapeutic products in Taiwan","volume":"33","author":"Pan","year":"2025","journal-title":"J Food Drug Anal"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib67","article-title":"Navigating regulatory and analytical challenges in live biotherapeutic product development and manufacturing","volume":"3","author":"Barberio","year":"2024","journal-title":"Front Microbiomes"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/frmbi.2025.1569348","article-title":"Chemistry, manufacturing, and controls for live microbial products: addressing classification challenges and enhancing process validation","volume":"4","author":"Slijkerman","year":"2025","journal-title":"Front Microbiomes"},{"issue":"5","key":"10.1016\/bs.pmbts.2026.01.008_bib69","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.BAD-0017-2017","article-title":"U.S. regulatory considerations for development of live biotherapeutic products as drugs","volume":"5","author":"Dreher-Lesnick","year":"2017","journal-title":"Microbiol Spectr"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib70","doi-asserted-by":"crossref","DOI":"10.4014\/jmb.2410.10054","article-title":"Live biotherapeutic products for metabolic diseases: development strategies, challenges, and future directions","volume":"35","author":"Min","year":"2025","journal-title":"J Microbiol Biotechnol"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115663","article-title":"Bioinspired approaches to encapsulate and deliver bacterial live biotherapeutic products","volume":"225","author":"Brittain","year":"2025","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/bs.pmbts.2026.01.008_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1151888","article-title":"Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development","volume":"14","author":"Sauna","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/bs.pmbts.2026.01.008_bib73","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nbt.4222","article-title":"Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria","volume":"36","author":"Isabella","year":"2018","journal-title":"Nat Biotechnol"}],"container-title":["Progress in Molecular Biology and Translational Science","Live Biotherapeutics: Advancing Microbial Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117326000086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117326000086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:29:34Z","timestamp":1791386974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117326000086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443431906"],"references-count":73,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2026.01.008","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}